Inozyme Pharma

  • TickerINZY
  • ISINUS45790W1080
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
 PRESS RELEASE
INZY INOZYME PHARMA (Health Care)

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the E...

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency INZ-701 was previously granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for ENPP1 Deficiency BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to INZ-701 for the treat...

David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
 PRESS RELEASE
INZY INOZYME PHARMA (Health Care)

Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business...

Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business Highlights – Filed Clinical Trial Application for INZ-701 for ABCC6 Deficiency in Europe; on track to initiate Phase 1/2 clinical trial in mid-2021 – – Published peer-reviewed preclinical data supporting INZ-701 as a potential treatment for ENPP1 Deficiency in Journal of Bone and Mineral Research – – Presented data from first-ever Burden of Illness Study for ENPP1 and ABCC6 Deficiencies at multiple medical conferences – – Cash, cash equivalents, and investments expected to enable continued operations into the fourth q...

 PRESS RELEASE
INZY INOZYME PHARMA (Health Care)

Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701...

Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency Results presented at the European Calcified Tissue Society Congress provide first evidence of increased plasma pyrophosphate (PPi) levels and reduced calcification with an enzyme replacement therapy in an animal model of PXE BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today presented preclinical data suggesting the utility of its lead clinical...

 PRESS RELEASE
INZY INOZYME PHARMA (Health Care)

Inozyme Pharma and Researchers from Thomas Jefferson University to Pre...

Inozyme Pharma and Researchers from Thomas Jefferson University to Present Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency at Two Upcoming Medical Conferences BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization disorders, today announced that preclinical data from a study examining INZ-701 for the potential treatment for ABCC6 Deficiency/Pseudoxanthoma elasticum (PXE) will be presented at the following upcoming medical con...

 PRESS RELEASE
INZY INOZYME PHARMA (Health Care)

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the E...

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency INZ-701 was previously granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for ENPP1 Deficiency BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to INZ-701 for the treat...

David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
 PRESS RELEASE
INZY INOZYME PHARMA (Health Care)

Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business...

Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business Highlights – Filed Clinical Trial Application for INZ-701 for ABCC6 Deficiency in Europe; on track to initiate Phase 1/2 clinical trial in mid-2021 – – Published peer-reviewed preclinical data supporting INZ-701 as a potential treatment for ENPP1 Deficiency in Journal of Bone and Mineral Research – – Presented data from first-ever Burden of Illness Study for ENPP1 and ABCC6 Deficiencies at multiple medical conferences – – Cash, cash equivalents, and investments expected to enable continued operations into the fourth q...

 PRESS RELEASE
INZY INOZYME PHARMA (Health Care)

Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701...

Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency Results presented at the European Calcified Tissue Society Congress provide first evidence of increased plasma pyrophosphate (PPi) levels and reduced calcification with an enzyme replacement therapy in an animal model of PXE BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today presented preclinical data suggesting the utility of its lead clinical...

 PRESS RELEASE
INZY INOZYME PHARMA (Health Care)

Inozyme Pharma and Researchers from Thomas Jefferson University to Pre...

Inozyme Pharma and Researchers from Thomas Jefferson University to Present Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency at Two Upcoming Medical Conferences BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization disorders, today announced that preclinical data from a study examining INZ-701 for the potential treatment for ABCC6 Deficiency/Pseudoxanthoma elasticum (PXE) will be presented at the following upcoming medical con...

 PRESS RELEASE
INZY INOZYME PHARMA (Health Care)

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the E...

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency INZ-701 was previously granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for ENPP1 Deficiency BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to INZ-701 for the treat...

David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
 PRESS RELEASE
INZY INOZYME PHARMA (Health Care)

Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business...

Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business Highlights – Filed Clinical Trial Application for INZ-701 for ABCC6 Deficiency in Europe; on track to initiate Phase 1/2 clinical trial in mid-2021 – – Published peer-reviewed preclinical data supporting INZ-701 as a potential treatment for ENPP1 Deficiency in Journal of Bone and Mineral Research – – Presented data from first-ever Burden of Illness Study for ENPP1 and ABCC6 Deficiencies at multiple medical conferences – – Cash, cash equivalents, and investments expected to enable continued operations into the fourth q...

 PRESS RELEASE
INZY INOZYME PHARMA (Health Care)

Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701...

Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency Results presented at the European Calcified Tissue Society Congress provide first evidence of increased plasma pyrophosphate (PPi) levels and reduced calcification with an enzyme replacement therapy in an animal model of PXE BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today presented preclinical data suggesting the utility of its lead clinical...

 PRESS RELEASE
INZY INOZYME PHARMA (Health Care)

Inozyme Pharma and Researchers from Thomas Jefferson University to Pre...

Inozyme Pharma and Researchers from Thomas Jefferson University to Present Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency at Two Upcoming Medical Conferences BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization disorders, today announced that preclinical data from a study examining INZ-701 for the potential treatment for ABCC6 Deficiency/Pseudoxanthoma elasticum (PXE) will be presented at the following upcoming medical con...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch